Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Fornaro

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
European Journal of Hospital Pharmacy : Science and Practice|March 4, 2021
Cost-saving effect of early less invasive surfactant administration versus continuous positive airway pressure therapy alone for preterm infants with respiratory distress syndromeCarlo Federici, Giulia Fornaro, Charles Christopher Roehr
Otology & Neurotology Open|March 22, 2024
The Value of Hearing Aids for the Italian NHS: A Cost-utility AnalysisGiulia Fornaro, Patrizio Armeni, Andrea Albera, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Oriana Ciani, Carlo Federici, Giulia Fornaro, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2021
Broadening the Concept of Value: A Scoping Review on the Option Value of Medical TechnologiesGiulia Fornaro, Carlo Federici, Carla Rognoni, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 19, 2020
Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical AnalysisAleksandra Torbica, Giulia Fornaro, Rosanna Tarricone, et al.
Clinical Therapeutics|June 28, 2020
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health ServicePatrizio Armeni, Ludovica Borsoi, Giulia Fornaro, et al.
Clinical Therapeutics|May 2, 2020
Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health ServicePatrizio Armeni, Ludovica Borsoi, Giulia Fornaro, et al.
BMC Anesthesiology|November 6, 2025
The economic burden of anesthetic-related adverse events: a systematic review and empirical analysisPatrizio Armeni, Francesco Costa, Giulia Fornaro, et al.
Cancers|January 21, 2023
The Impact of Surgical Experience in VATS Lobectomy on Conversion and Patient Quality of Life: Results from a Comprehensive National Video-Assisted Thoracic Surgical DatabaseLuca Bertolaccini, Giulia Fornaro, Oriana Ciani, et al.
BMC Health Services Research|May 13, 2023
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?Michael Drummond, Oriana Ciani, Giulia Fornaro, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
European Journal of Hospital Pharmacy : Science and Practice|March 4, 2021
Cost-saving effect of early less invasive surfactant administration versus continuous positive airway pressure therapy alone for preterm infants with respiratory distress syndromeCarlo Federici, Giulia Fornaro, Charles Christopher Roehr
Otology & Neurotology Open|March 22, 2024
The Value of Hearing Aids for the Italian NHS: A Cost-utility AnalysisGiulia Fornaro, Patrizio Armeni, Andrea Albera, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Oriana Ciani, Carlo Federici, Giulia Fornaro, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2021
Broadening the Concept of Value: A Scoping Review on the Option Value of Medical TechnologiesGiulia Fornaro, Carlo Federici, Carla Rognoni, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 19, 2020
Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical AnalysisAleksandra Torbica, Giulia Fornaro, Rosanna Tarricone, et al.
Clinical Therapeutics|June 28, 2020
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health ServicePatrizio Armeni, Ludovica Borsoi, Giulia Fornaro, et al.
Clinical Therapeutics|May 2, 2020
Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health ServicePatrizio Armeni, Ludovica Borsoi, Giulia Fornaro, et al.
BMC Anesthesiology|November 6, 2025
The economic burden of anesthetic-related adverse events: a systematic review and empirical analysisPatrizio Armeni, Francesco Costa, Giulia Fornaro, et al.
Cancers|January 21, 2023
The Impact of Surgical Experience in VATS Lobectomy on Conversion and Patient Quality of Life: Results from a Comprehensive National Video-Assisted Thoracic Surgical DatabaseLuca Bertolaccini, Giulia Fornaro, Oriana Ciani, et al.
BMC Health Services Research|May 13, 2023
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?Michael Drummond, Oriana Ciani, Giulia Fornaro, et al.
Pageof 2